Why BCR-ABL1 Remains the Defining Target in CML

Chronic myeloid leukemia is caused by a reciprocal chromosomal translocation between chromosomes 9 and 22 — the Philadelphia (Ph) chromosome — generating the BCR-ABL1 oncogenic fusion gene. The resulting BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives proliferation, impaired apoptosis, and altered adhesion of myeloid progenitor cells. Left untreated, the disease progresses through a chronic phase, an accelerated phase, and a lethal blast crisis.

Patent filings from The Regents of the University of California across multiple Japanese jurisdictions catalog the foundational mutant BCR-ABL biology, enumerating clinically detected resistance mutations including M224V, L248V, G250E, Q252R, Y253H, E255K, T315I, T315N, F317L, F359V, H396P, H396R, and F486S. Of these, the T315I “gatekeeper” mutation is specifically highlighted across multiple records as conferring resistance to all first- and second-generation TKIs — imatinib, nilotinib, dasatinib, and bosutinib — making it the primary unresolved clinical challenge in the field, as tracked by organisations including NIH and EMA.

The BCR-ABL1 kinase domain is the primary target of first- through third-generation ATP-competitive TKIs. The mechanistic basis for resistance is well-established: imatinib binds the ATP pocket only when the activation loop is in a closed, inactive conformation. Resistance mutations disrupt this conformational requirement, abrogating inhibitor binding. University of California patent filings identify T315I BCR-ABL as the primary resistance-associated mutant (MARS), a designation that has driven successive rounds of inhibitor design over two decades.

The STAMP Mechanism: Allosteric BCR-ABL Inhibition Explained

STAMP inhibitors — Specifically Targeting the ABL Myristoyl Pocket — work by binding the N-terminal myristoyl-binding pocket of ABL1, a site entirely distinct from the ATP-binding cleft, and re-establishing the inactive kinase conformation without competing with ATP. This mechanistic orthogonality is the defining advantage of the class: because STAMP inhibitors do not compete for the ATP site, the resistance mutations that defeat imatinib, nilotinib, dasatinib, and bosutinib do not automatically confer cross-resistance.

The scientific rationale for targeting this site is explicitly described in Novartis AG patent filings in ES and CN jurisdictions, which reference the landmark 2010 Nature work by Zhang et al. showing that combining allosteric inhibitors with ATP-binding-site inhibitors can overcome resistance not addressable by either modality alone. This dual-inhibition paradigm — combining a STAMP inhibitor with an ATP-competitive TKI — is an active direction signalled by Novartis patent claims structured to encompass such combinations.

“Combining allosteric myristoyl-pocket inhibitors with ATP-binding-site inhibitors can overcome resistance not addressable by either modality alone — the mechanistic basis for the STAMP + TKI combination strategy.”

A third allosteric approach — distinct from both ATP-competitive and myristoyl-pocket inhibition — is described in a University of Utah Research Foundation patent (CA, 2015): peptides comprising the BCR-ABL coiled-coil (CC) oligomerization domain with alpha-helix-stabilising moieties. These act as competitive inhibitors of BCR-ABL oligomerization, disrupting a site required for full oncogenic activation. This approach is preclinical and patent-driven, representing a less commercially mature but scientifically distinct mechanistic avenue tracked by academic groups aligned with institutions such as NIH.

Patent Landscape: Novartis, Enliven, and the TERN-701 Lineage

The STAMP allosteric inhibitor IP landscape is dominated by Novartis AG, with Enliven Incorporated emerging as the key next-generation challenger through the 7-azaindole chemical series covering TERN-701. Understanding the patent geography is essential for any drug developer or IP strategist working in this space.

Novartis AG is the dominant patent assignee for STAMP allosteric BCR-ABL inhibition. Active patents in ES (2017, 2018) and CN jurisdictions cover formula-I compounds and benzamide derivatives targeting ABL1, ABL2, and BCR-ABL1 via the myristoyl-binding pocket. These filings represent the foundational IP underpinning asciminib’s commercial development and explicitly describe the allosteric mechanism as a solution to the inadequacy of ATP-competitive inhibitors against resistance mutants including T315I.

Enliven Incorporated’s active 2023 JP patent on 7-azaindole-class BCR-ABL inhibitors is the most directly TERN-701-relevant filing in the dataset. The patent specifically acknowledges T315I resistance to all second-generation TKIs and notes that only one current therapeutic option exists for T315I-bearing patients (ponatinib). The filing date is consistent with clinical-stage development activity. No clinical outcome data for TERN-701 appear in the retrieved dataset.

Foundation Medicine’s WO (2023) and US pending (2025) patents on ABL1 fusions explicitly reference asciminib (Rea et al., Blood, 2021) alongside olverembatinib and vodobatinib as clinical-stage agents for TKI-resistant CML, providing cross-referenced pipeline documentation. Nerviano Medical Sciences holds JP and CN patents (2009–2013) on ATP-competitive tetrahydropyrrolo[3,4-c]pyrazole compounds with T315I activity — an earlier-generation approach with inactive legal status suggesting earlier-stage pipeline activity.

Clinical Evidence: What ASCEMBL Tells Us About STAMP Inhibition

The ASCEMBL Phase 3 trial provides the most direct clinical validation of the STAMP mechanism in the retrieved dataset. After ≥2 years of follow-up, asciminib (40 mg twice daily) demonstrated superior efficacy and better safety and tolerability than bosutinib (500 mg once daily) in CML-CP patients who had failed two or more prior TKIs. Major molecular response (MMR) rates were consistently higher with asciminib across major demographic and prognostic subgroups, as reported by Universitätsklinikum Jena (2023).

Additional clinical context is provided by the ENESTcmr Phase 3 study (Universidade Federal do Rio de Janeiro, 2017), which demonstrated that switching from imatinib to nilotinib in imatinib-persistent patients yields sustained deep molecular responses at 48 months — including MR4 and MR4.5 — establishing the clinical rationale for second-line TKI sequencing in patients who do not achieve sufficient depth of response on first-line therapy.

Translational mechanistic data from the University of Utah (2013) shows that transient, potent BCR-ABL1 inhibition — as with once-daily dasatinib despite its short half-life — can induce durable CML cell death through a phenomenon termed “oncogenic shock,” informing rational dosing and combination design. The same group (2015) characterised radotinib’s activity against a panel of BCR-ABL1 mutants, providing comparative preclinical benchmarking relevant to next-generation inhibitor evaluation. These findings are consistent with the broader framework for kinase inhibitor pharmacodynamics described in guidance from FDA.

Preclinical combination evidence from Kyoto University Hospital (2016) demonstrates in vitro synergy between the pan-HDAC inhibitor panobinostat and ponatinib in T315I-bearing Ba/F3 cells, providing a translational-stage signal for HDAC inhibitor plus TKI combinations. No clinical data for this combination appear in the retrieved dataset. The dataset contains no direct clinical data for TERN-701 specifically; the Enliven JP patent (2023) does not report clinical outcomes, and the retrieved results do not include regulatory submission data for TERN-701.

Resistance Beyond the Kinase Domain: Emerging Targets and Combinations

BCR-ABL-independent resistance mechanisms and leukemic stem cell (LSC) persistence are increasingly recognised as the next frontier in CML — and the patent dataset reflects a parallel wave of academic IP activity targeting these mechanisms alongside, or instead of, the BCR-ABL kinase domain itself.

Leukemic Stem Cell-Directed Combinations

University of Glasgow WO (2024) and US pending (2026) patents propose mitochondrial pyruvate carrier (MPC) inhibitors as agents that selectively target CML LSCs by exploiting their metabolic dependency on mitochondrial pyruvate transport — independently of and complementary to BCR-ABL inhibition. University of Bern’s US patent (2019) describes combining WNT signalling pathway inhibitors with BCR-ABL1 TKIs to target LSCs through a non-kinase pathway. Kanazawa University (JP, 2013) identifies TGF-β–Smad signalling as a pathway sustaining CML LSCs independently of BCR-ABL activity, and proposes a selective TGF-β–Smad inhibitor combined with a TKI to eliminate LSCs and prevent relapse.

Novel Biomarkers and Post-Transcriptional Targets

Seoul National University Research Foundation active JP patents (2025) describe FAM167A mRNA expression as a biomarker for BCR-ABL-independent TKI resistance in CML, with targeting FAM167A claimed as a therapeutic strategy for this resistance subset. The Chinese Academy of Medical Sciences CN patent (2021) identifies PABPC1 (poly(A)-binding protein cytoplasmic 1) as a regulator of BCR-ABL translation via promotion of eIF4G–eIF4E interaction and ribosome assembly. Knockdown of PABPC1 in imatinib-resistant CML lines inhibits BCR-ABL translation, suppresses cell cycle progression, and promotes apoptosis — establishing a post-transcriptional resistance mechanism independent of kinase domain targeting. These emerging biomarker-stratified approaches are consistent with broader precision oncology frameworks outlined by bodies such as WHO.

Strategic Implications for Drug Developers and IP Teams

The STAMP allosteric mechanism is well-IP-protected by Novartis, with multiple active patent families across ES and CN jurisdictions covering structural series relevant to asciminib. Competitors developing next-generation allosteric inhibitors — such as Enliven’s TERN-701, covered by the 7-azaindole JP patent (2023) — will need to navigate freedom-to-operate around Novartis’s myristoyl-pocket IP while differentiating on selectivity, T315I coverage, CNS penetration, or combination compatibility.

T315I remains the critical unmet need driving next-generation inhibitor development. Retrieved results across Enliven, Nerviano, and Foundation Medicine filings all specifically flag T315I as the key resistance liability of current approved agents. Compounds with potent T315I activity while maintaining allosteric binding differentiation — as TERN-701 is positioned — represent a high-value IP and clinical positioning target.

“Clinical evidence in the dataset supports asciminib (ASCEMBL, Phase 3) as the validated proof-of-concept for STAMP inhibition — establishing the clinical bar that TERN-701 and other next-generation allosteric agents must exceed.”

Combination strategies targeting leukemic stem cells alongside BCR-ABL represent an emerging IP frontier. University of Glasgow (MPC inhibitors), University of Bern (WNT inhibition), and Kanazawa University (TGF-β) all filed or have active patents in LSC-directed combination approaches. Academic institutions — not large pharma — are currently leading this direction in the dataset, suggesting licensing or partnership opportunities for companies seeking to differentiate beyond kinase domain inhibition. This dynamic mirrors broader trends in oncology combination IP documented by organisations such as ASCO.

BCR-ABL-independent resistance mechanisms — FAM167A, PABPC1, TGF-β signalling — are emerging as diagnostically and therapeutically actionable. For IP strategists and drug developers, biomarker-stratified approaches to TKI-resistant CML represent an opportunity space, particularly as companion diagnostic patents from Seoul National University Research Foundation (2025) appear to precede or accompany therapeutic composition filings. Developers can track these emerging filings and cross-reference them with clinical-stage assets using PatSnap’s innovation intelligence platform.

The ASCEMBL Phase 3 data establishes asciminib’s MMR superiority over bosutinib in heavily pre-treated CML-CP patients as the validated clinical benchmark for the STAMP class. Next-generation allosteric agents including TERN-701 will need to demonstrate differentiated T315I activity, deeper molecular response rates, or improved tolerability profiles to carve a distinct clinical and commercial position — a challenge that requires both robust IP strategy and deep mechanistic differentiation. Teams can access the PatSnap resources library for additional guidance on navigating oncology patent landscapes.